bluebird bio Rebrands as Genetix Biotherapeutics Following Private Equity Buyout
bluebird bio; Genetix Biotherapeutics; private equity buyout; Carlyle; SK Capital Partners; gene therapy; rebranding; FDA-approved therapies; David Meek; sickle cell disease; β-thalassemia; cerebral adrenoleukodystrophy; commercial execution; manufacturing investment
Novo Nordisk Awaits FDA Decision on Oral Wegovy Pill for Obesity
Novo Nordisk; Wegovy; oral semaglutide; FDA approval; obesity treatment; GLP-1 pill; weight loss; cardiovascular risk
Roche Acquires 89bio with $2.4 Billion Buyout to Enter FGF21 MASH Therapeutics Space
Roche; 89bio; acquisition; FGF21; pegozafermin; MASH; metabolic dysfunction-associated steatohepatitis; liver disease; biotech; contingent value rights; cardiometabolic diseases
A Concerning Pattern: Pharma Mulls UK Divestments as Government Action Lags in Life Sciences
UK life sciences; pharmaceutical divestment; Merck; AstraZeneca; Sanofi; Eli Lilly; R&D investment; drug pricing; government policy; NHS drug spending
GSK Commits $30 Billion to Bolster U.S. R&D and Manufacturing
GSK; $30 billion investment; U.S. expansion; R&D; manufacturing; biopharma; supply chain; advanced digital technologies
ArsenalBio Lays Off 50% of Staff in Major Strategic Pivot
ArsenalBio; layoffs; biotech; staff reduction; restructuring; cell therapy; AB-2100; clinical trials; Bristol Myers Squibb partnership
Novo Nordisk and Bristol Myers Squibb Announce Major Layoffs in New Jersey
Novo Nordisk; Bristol Myers Squibb; layoffs; New Jersey; pharmaceutical industry; restructuring; job cuts; Ozempic; Wegovy; workforce reduction
Priovant Announces Successful Phase III Results for Brepocitinib in Dermatomyositis (VALOR Study)
Priovant; Roivant; brepocitinib; Phase III; VALOR study; dermatomyositis; clinical trial; Total Improvement Score; TIS; steroid reduction; cutaneous remission; NDA filing
AstraZeneca’s Saphnelo Succeeds in Phase III as Self-Injectable Lupus Treatment
AstraZeneca; Saphnelo; anifrolumab; Phase III; TULIP-SC trial; systemic lupus erythematosus; SLE; self-injectable; subcutaneous; clinical trial; disease activity reduction
Aditum forms new company for China-sourced asset in $1B deal
Aditum; China-sourced asset; $1B deal; newco; Mabwell; dyslipidemia; vascular disorders; biotech licensing; cross-border pharma